CRP: Star trekking the galaxy of risk markers

The Lancet

Volumn 377, Issue 9764, 2011, Pages 441-442

  Després, Jean Pierre ^a,b  

^a L'Institut Universitaire   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); HIGH RISK POPULATION; HUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR;

EID: 79551681740     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)62316-1     Document Type: Note

References (16)

1. DI Buckley, R Fu, M Freeman, K Rogers, M Helfand C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force Ann Intern Med 151 2009 483 495
2. PM Ridker, RJ Glynn, CH Hennekens C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction Circulation 97 1998 2007 2011
3. PM Ridker, JE Buring, N Rifai, NR Cook Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score JAMA 297 2007 611 619
4. The Emerging Risk Factors Collaboration C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis Lancet 375 2010 132 140
5. R Detrano, AD Guerci, JJ Carr Coronary calcium as a predictor of coronary events in four racial or ethnic groups N Engl J Med 358 2008 1336 1345
6. S Gupta, JD Berry, CR Ayers Left ventricular hypertrophy, aortic wall thickness, and lifetime predicted risk of cardiovascular disease: the Dallas Heart Study JACC Cardiovasc Imaging 3 2010 605 613
7. PM Ridker, E Danielson, FA Fonseca for the JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
8. J Genest, R McPherson, J Frohlich 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations Can J Cardiol 25 2009 567 579
9. BJ Arsenault, SM Boekholdt, P Deedwania C-reactive protein and lipid levels to predict the risk of coronary heart disease in statin-treated stable coronary patients: prospective results from the Treating to New Targets (TNT) study Circulation 122 suppl 2010 A14207 (abstr).
10. Sever PS, Poulter NR, Chang CL, et al. Evaluation of C-reactive protein, prior to and on-treatment, as a predictor of benefit from atorvastatin: observations from ASCOT. American Heart Association scientific sessions; November, 2010, Chicago, IL. Late-breaking clinical trials IV.
11. Heart Protection Study Collaborative Group C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Lancet 2011 10.1016/S0140-6736(10)62174- 5 published online Jan 28.
12. PM Ridker, J MacFadyen, P Libby, RJ Glynn Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) Am J Cardiol 106 2010 204 209
13. I Lemieux, A Pascot, D Prud'homme Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity Arterioscler Thromb Vasc Biol 21 2001 961 967
14. JP Després, I Lemieux Abdominal obesity and metabolic syndrome Nature 444 2006 881 887
15. JP Després Bringing JUPITER down to earth Lancet 373 2009 1147 1148
16. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22